Trevi Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Trevi Therapeutics, Inc. (TRVI) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 30.81 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-12
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 30.81M shares, a 58.65% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 30.19M shares, a 63.84% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 21.61M shares, a 19.15% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 20.12M shares, a 12.83% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 22.84M shares, a 26.48% increase from fiscal 2020.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 18.06M shares, a 53.88% increase from fiscal 2019.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 11.74M shares, a 2581.79% increase from fiscal 2018.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 437.61K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 30.81M shares 10-Q · filed 2022-05-12 | 30.50M shares derived: average of 2 quarters · filed 2022-05-12 | 27.54M shares derived: average of 3 quarters · filed 2022-05-12 | 25.68M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 30.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 25.90M shares derived: average of 2 quarters · filed 2022-03-17 | 23.97M shares derived: average of 3 quarters · filed 2022-03-17 | 22.84M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 21.61M shares 10-Q · filed 2021-11-10 | 20.87M shares derived: average of 2 quarters · filed 2021-11-10 | 20.39M shares 10-Q · filed 2021-11-10 | 19.89M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | 20.12M shares 10-Q · filed 2021-08-12 | 19.77M shares 10-Q · filed 2021-08-12 | 19.32M shares derived: average of 3 quarters · filed 2022-05-12 | 19.03M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | 19.42M shares 10-Q · filed 2022-05-12 | 18.92M shares derived: average of 2 quarters · filed 2022-05-12 | 18.66M shares derived: average of 3 quarters · filed 2022-05-12 | 18.45M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | 18.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 18.28M shares derived: average of 2 quarters · filed 2022-03-17 | 18.13M shares derived: average of 3 quarters · filed 2022-03-17 | 18.06M shares 10-K · filed 2022-03-17 |
| 2020-09-30 | 18.13M shares 10-Q · filed 2021-11-10 | 17.99M shares derived: average of 2 quarters · filed 2021-11-10 | 17.94M shares 10-Q · filed 2021-11-10 | 17.93M shares derived: average of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | 17.84M shares 10-Q · filed 2021-08-12 | 17.84M shares 10-Q · filed 2021-08-12 | 17.86M shares derived: average of 3 quarters · filed 2021-08-12 | 17.85M shares derived: average of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | 17.83M shares 10-Q · filed 2021-05-13 | 17.87M shares derived: average of 2 quarters · filed 2021-05-13 | 17.86M shares derived: average of 3 quarters · filed 2021-05-13 | 16.04M shares derived: average of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | 17.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 17.87M shares derived: average of 2 quarters · filed 2021-03-25 | 15.44M shares derived: average of 3 quarters · filed 2021-03-25 | 11.74M shares 10-K · filed 2021-03-25 |
| 2019-09-30 | 17.83M shares 10-Q · filed 2020-11-12 | 14.20M shares derived: average of 2 quarters · filed 2020-11-12 | 9.68M shares 10-Q · filed 2020-11-12 | 7.32M shares derived: average of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | 10.57M shares 10-Q · filed 2020-08-13 | 5.54M shares 10-Q · filed 2020-08-13 | 3.82M shares derived: average of 3 quarters · filed 2020-08-13 | 2.97M shares derived: average of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | 444.13K shares 10-Q · filed 2020-05-07 | 441.38K shares derived: average of 2 quarters · filed 2020-05-07 | 440.45K shares derived: average of 3 quarters · filed 2020-05-07 | 439.99K shares derived: average of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | 438.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 438.61K shares derived: average of 2 quarters · filed 2020-03-16 | 438.61K shares derived: average of 3 quarters · filed 2020-03-16 | 437.61K shares 10-K · filed 2020-03-16 |
| 2018-09-30 | 438.61K shares 10-Q · filed 2019-11-14 | 438.61K shares derived: average of 2 quarters · filed 2019-11-14 | 437.27K shares 10-Q · filed 2019-11-14 | |
| 2018-06-30 | 438.61K shares 10-Q · filed 2019-08-12 | 436.60K shares 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | 434.57K shares 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |